Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of NPT200-11 in Healthy Subjects
NCT02606682Phase 1Completed
- Sponsor
- Neuropore Therapies, Inc.
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of minzasolmin in Parkinson's disease (PD) (7 cohorts), sponsored by Neuropore Therapies, Inc. Primary endpoint: Safety and Tolerability. Started Jul 2015; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02606682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606682.